Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 2/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 6/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | ABL1 | P00519 | 4/20 | 0.34 |
| ▸ | HCK | P08631 | 4/20 | 0.34 |
| ▸ | SRC | P12931 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.34 |
| ▸ | MTOR | P42345 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.34 |
| ▸ | PRKDC | P78527 | 4/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142936 | 0.91 | SOS1 (0.39) | PDE9ASOS1EGFRKDRIDH1 | |
| SCHEMBL20142972 | 0.85 | SOS1 (0.39) | SOS1EGFRKDRBTK | |
| SCHEMBL20138681 | 0.84 | EPAS1 (0.34) | EGFRPIK3CDABL1HCKSRC | |
| SCHEMBL20138698 | 0.77 | ADORA1 (0.36) | PDE9ASOS1BTK | |
| SCHEMBL20159269 | 0.74 | — | — | |
| SCHEMBL20154264 | 0.74 | EPAS1 (0.34) | — | |
| SCHEMBL20138791 | 0.73 | KDR (0.41) | SOS1EGFRKDR | |
| SCHEMBL23492529 | 0.72 | PSEN1 (0.50) | PI4KB | |
| SCHEMBL23492532 | 0.72 | PSEN1 (0.50) | PI4KB | |
| SCHEMBL23492534 | 0.72 | PSEN1 (0.50) | PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790149-B | Phenoxytriazoles | 豪夫迈·罗氏有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538516-A1 | PHENOXYTRIAZOLES | F. Hoffmann-La Roche AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087018-A1 | PHENOXYTRIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087018-A1 | PHENOXYTRIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | PDE9A 2679/4885SOS1 799/4885TGFBR1 794/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | PDE9A 2713/4885SOS1 839/4885TGFBR1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.